Taiwan Stock Exchange · Healthcare
Adimmune stock from India: price, numbers and tax
Adimmune (4142) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Adimmune at a glance
- Price
- NT$18.10-NT$0.15 (0.82%)
- Market cap
- NT$7.63B
- Day range
- NT$18.05 – NT$18.35
- P/E
- -53.24
- Dividend yield
- None
- Volume
- 552.29K
- 1 month
- +2.26%
- 6 months
- -3.72%
- YTD
- -4.49%
- 1 year
- -4.99%
- 5 years
- -64.44%
Adimmune statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$1.4B | NT$1.6B | NT$1.8B | NT$2.3B | NT$1.6B |
| Gross profit | NT$288.5M | NT$448.1M | NT$410.9M | NT$891.1M | NT$464.1M |
| Operating income | −NT$359.6M | −NT$299.1M | −NT$722.7M | NT$98.6M | −NT$54.1M |
| Net income | −NT$239.9M | −NT$242.8M | −NT$639.9M | NT$291.0M | NT$43.1M |
| Earnings per share | −NT$0.57 | −NT$0.58 | −NT$1.52 | NT$0.68 | NT$0.10 |
| EBITDA | −NT$144.7M | −NT$84.3M | −NT$512.4M | NT$438.1M | NT$254.9M |
| Total assets | NT$8.2B | NT$8.5B | NT$9.5B | NT$9.1B | NT$8.0B |
| Total debt | NT$2.8B | NT$2.6B | NT$3.1B | NT$2.3B | NT$1.3B |
| Cash and short-term investments | NT$2.2B | NT$2.5B | NT$2.5B | NT$3.0B | NT$2.9B |
| Shareholders' equity | NT$4.9B | NT$5.2B | NT$5.5B | NT$6.1B | NT$6.1B |
| Operating cash flow | −NT$5.4M | NT$668.5M | −NT$892.3M | −NT$292.0M | −NT$480.5M |
| Free cash flow | −NT$242.2M | NT$513.3M | −NT$1.1B | −NT$711.6M | −NT$1.3B |
| Capital expenditure | −NT$236.7M | −NT$155.2M | −NT$221.5M | −NT$419.6M | −NT$845.3M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| CHO Pharma | 6586.TWO | $116.00 | $24.83B |
| AP Biosciences | 6945.TWO | $143.00 | $13.87B |
| PharmaEngine | 4162.TWO | $55.30 | $7.95B |
| Acepodia | 6976.TWO | $12.80 | $7.43B |
| Sinphar Pharmaceutical | 1734.TW | NT$32.10 | NT$6.47B |
| TaiGen Biopharmaceuticals | 4157.TWO | $8.73 | $6.21B |
| OBI Pharma | 4174.TWO | $43.10 | $5.67B |
| Mycenax Biotech | 4726.TWO | $23.40 | $4.84B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Adimmune from India
What Adimmune does
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Adimmune operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Adimmune shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.